NCT05622487

Brief Summary

The aim of this study; to investigate the effects of neural therapy and kinesio taping treatments on pain, functional status and quality of life in women with fibromyalgia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2021

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 6, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 18, 2022

Completed
Last Updated

November 18, 2022

Status Verified

November 1, 2022

Enrollment Period

8 months

First QC Date

August 6, 2022

Last Update Submit

November 14, 2022

Conditions

Keywords

FibromyalgiaNeural TherapyKinesio Taping

Outcome Measures

Primary Outcomes (3)

  • Visual Analogue Scale pain (0-10 point).

    Higher scores mean a worse outcome

    up to 3 month

  • Fibromyalgia Impact Questionnaire (0-100 point)

    The Fibromyalgia Impact Questionnaire was developed to assess the current functional status of women with FMS. Higher scores mean a worse outcome

    up to 3 month

  • Pain measurement with manual algometer

    18 tender points in 1990 ACR FMS criteria will be evaluated with a manual algometer. Higher scores mean a worse outcome

    up to 3 month

Secondary Outcomes (5)

  • Beck Depression Inventory (0-63 point)

    up to 3 month

  • Beck Anxiety Inventory (0-63 point)

    up to 3 month

  • Central Sensitisation Inventory (0-100 point)

    up to 3 month

  • Health Assessment Questionnaire (0-60 point)

    up to 3 month

  • Short Form-36 (0-100 point)

    up to 3 month

Study Arms (2)

Neural Therapy

ACTIVE COMPARATOR

Segmental neural therapy will be administered with intradermal 0.5% lidocaine from cervical 1st to sacral 1st vertebra and upper trapezius region with quaddel injections.. Sham kinesio taping will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.

Other: Neural Therapy

Kinesio Taping

ACTIVE COMPARATOR

Kinesio taping will be applied with muscle inhibition technique by stretching from the origin to the insertion of the upper trapezius, cervical thoracic and lumbar paravertebral muscles. Sham neural therapy will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.

Other: Kinesio taping

Interventions

Neural therapy is a form of treatment that aims to act on the autonomic nervous system, by injecting local anesthetics into certain parts of the body.

Neural Therapy

Kinesiotape is used for injury prevention, rehabilitation and performance enhancement. It has been shown to be clinically effective in increasing joint movements, increasing muscle activity, inducing muscle maximum torque earlier, and improving functional performance

Kinesio Taping

Eligibility Criteria

Age18 Years - 55 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • To be diagnosed with fibromyalgia according to the ACR 2016 diagnostic criteria.
  • Being a woman between the ages of 18 and 55.
  • No change in the medical treatment he received for fibromyalgia syndrome during the study
  • To be able to come to treatment 1 day a week for 6 weeks

You may not qualify if:

  • Presence of known central nervous system or peripheral nervous system disease, progressive neurological deficit
  • Peripheral venous insufficiency, coagulopathies and anticoagulant drug use
  • Loss of sensation, loss of position sense, unhealed fracture or open surgical wound
  • Uncontrolled hypertension and uncontrolled diabetes
  • Be in major depression
  • Cognitive impairment that causes difficulty following simple commands
  • Pregnancy
  • Be in menopause
  • Allergy to local anesthetics and kinesio taping
  • Open wound or infection at the application site

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Istanbul, Fatıh, 34034, Turkey (Türkiye)

Location

Istanbul University

Istanbul, 3409, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Fibromyalgia

Interventions

Anesthesia, Local

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Anesthesia, ConductionAnesthesiaAnesthesia and Analgesia

Study Officials

  • Ayşegül Ketenci, Professor

    Study Director

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 6, 2022

First Posted

November 18, 2022

Study Start

March 1, 2021

Primary Completion

November 1, 2021

Study Completion

January 1, 2022

Last Updated

November 18, 2022

Record last verified: 2022-11

Locations